Status: current, Defined. Date: 31-Mar 2019. Module: Australian Medicines Terminology module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3262541000168115 | Takhzyro (lanadelumab 300 mg / 2 mL) injection, 2 mL vial (trade product unit of use) | en | Fully specified name | Active | Case sensitive | Australian Medicines Terminology module |
| 3262551000168118 | Takhzyro 300 mg/2 mL injection, 2 mL vial | en | Synonym | Active | Case sensitive | Australian Medicines Terminology module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Takhzyro 300 mg/2 mL injection, 2 mL vial | Is a | Takhzyro | true | Inferred relationship | Some | ||
| Takhzyro 300 mg/2 mL injection, 2 mL vial | Is a | lanadelumab 300 mg/2 mL injection, vial | true | Inferred relationship | Some | ||
| Takhzyro 300 mg/2 mL injection, 2 mL vial | Is a | trade product unit of use | true | Inferred relationship | Some | ||
| Takhzyro 300 mg/2 mL injection, 2 mL vial | has manufactured dose form | injection | true | Inferred relationship | Some | ||
| Takhzyro 300 mg/2 mL injection, 2 mL vial | has unit of use | vial | true | Inferred relationship | Some | 930210255 | |
| Takhzyro 300 mg/2 mL injection, 2 mL vial | has Australian BoSS | lanadelumab | true | Inferred relationship | Some | 930210254 | |
| Takhzyro 300 mg/2 mL injection, 2 mL vial | has intended active ingredient | lanadelumab | true | Inferred relationship | Some | 930210254 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Takhzyro 300 mg/2 mL injection, 2 mL vial | has TPUU | True | Takhzyro 300 mg/2 mL injection, 2 mL vial | Inferred relationship | Some | 1 |
| Takhzyro 300 mg/2 mL injection, 2 mL vial | has TPUU | True | Takhzyro 300 mg/2 mL injection, 2 mL vial | Inferred relationship | Some | 1 |
Reference Sets
Black Triangle Scheme reference set
Trade product unit of use reference set
FHIR